Chronic myelogenous leukemia

Current Opinion in Oncology

Volumn 15, Issue 1, 2003, Pages 10-15

  O'Dwyer, Michael E ^a  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; BUSULFAN; CYTARABINE; HYDROXYUREA; IMATINIB; INTERFERON; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ALGORITHM; BLOOD TOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIAGNOSTIC VALUE; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; NEUTROPENIA; PRIORITY JOURNAL; PROBLEM SOLVING; REVIEW; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES; STEM CELL TRANSPLANTATION;

EID: 0037249410     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200301000-00002     Document Type: Review

References (54)

1. Silver RT, Woolf SH, Hehlmann R, et al.: An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999, 94:1517-1536.
2. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a metaanalysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst 1997, 89:1616-1620.
3. Bonifazi F, de Vivo A, Rosti G, et al.: Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001, 98:3074-3081. • Extended follow-up shows that many low-risk and intermediate-risk patients achieving complete responses to interferon can have durable long-term remissions.
4. Kantarjian HM, Giles FJ, O'Brien SM, et al.: Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematol Oncol Clin North Am 1998, 12:31-80.
5. Shepherd P, Kluin-Nelemans HC, Richards S, et al.: A randomised comparison of low or high dose IFN-α in newly diagnosed CML patients shows no differences in major cytogenetic response rate or survival between the two groups: results of MRC CML V & HOVON 20 trials. Blood 2001, 98:727a.
6. Talpaz M, O'Brien S, Rose E, et al.: Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 2001, 98:1708-1713.
7. Guilhot F, Chastang C, Michallet M, et al.: Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997, 337:223-229.
8. Baccarani M, Rosti G, de Vivo A, et al.: A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 2002, 99:1527-1535.
9. Druker BJ, Lydon NB: Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000, 105:3-7.
10. O'Dwyer ME, Mauro MJ, Druker BJ: Recent advancements in the treatment of chronic myelogenous leukemia. Annu Rev Med 2002, 53:369-381.
11. Kantarjian H, Sawyers C, Hochhaus A, et al.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645-652. • • This pivotal phase II study confirms the promise of the phase I study, establishing imatinib as an effective treatment after interferon failure in chronic phase patients.
12. Talpaz M, Silver RT, Druker BJ, et al.: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002, 99:1928-1937. • In addition to showing activity in accelerated phase, this article shows that, at least in this group of patients, higher doses of imatinib are associated with a more favorable outcome.
13. O'Dwyer ME, Mauro MJ, Kurilik G, et al.: The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 2002, 100:1628-1633.
14. Sawyers CL, Hochhaus A, Feldman E, et al.: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99:3530-3539. • This study shows that despite remarkable activity as a single agent, the vast majority of patients with advanced phase disease relapse with resistant disease.
15. Druker BJ: STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN) + cy tarabine as initial therapy for patients with CML: results of a randomized study [abstract]. Proc ASCO 2002, 21:1a. • • Establishes a new standard of care for nontransplant therapy of CML.
16. Kantarjian H, Jorge C, O'Brien S, et al.: High rates of early major and complete cytogenetic responses with imatinib mesylate therapy given at 400 mg or 800 mg orally daily in patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase [abstract]. Proc ASCO 2002, 21:261a.
17. Marin D, Bua M, Marktel S, et al.: The combination of cytogenetic response after 6 months treatment with STI571 and the presence of cytopenias in patients with CML in chronic phase resistant to or intolerant of interferon-alfa defines four different prognostic groups. [abstract]. Blood 2001, 98:846a.
18. Merx K, Kreil S, Lahaye T, et al.: Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response to STI571 in chronic phase CML patients [abstract]. Blood 2001, 98:846a-847a.
19. Braziel RM, Launder TM, Druker BJ, et al.: Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood 2002, 100:435-441.
20. Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, et al.: Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 2002, 16:1390-1393.
21. O'Dwyer ME, Gatter KM, Loriaux M, et al.: The demonstration of clonal abnormalities in Philadelphia chromosome negative cells following imatinib mesylate induced major cytogenetic responses in patients with chronic myeloid leukemia. Leukemia 2003, in press.
22. Mauro MJ, Kurilik G, Balleisen S, et al.: Myeloid growth factors for neutropenia during imatinib mesylate (STI571) therapy for CML: preliminary evidence of safety and efficacy [abstract]. Blood 2001, 98:139a.
23. Druker BJ, Sawyers CL, Capdeville R, et al.: Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program) 2001:87-112.
24. Gorre ME, Sawyers CL: Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 2002, 9:303-307.
25. Gambacorti-Passerini C, Barni R, le Coutre P, et al.: Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000, 92:1641-1650.
26. Jorgensen HG, Elliott MA, Allan EK, et al.: Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood 2002, 99:713-715.
27. le Coutre P, Tassi E, Varella-Garcia M, et al.: Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000, 95:1758-1766.
28. Mahon FX, Deininger MW, Schultheis B, et al.: Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000, 96:1070-1079.
29. Weisberg E, Griffin JD: Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000, 95:3498-3505.
30. Gorre ME, Mohammed M, Ellwood K, et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880. • • First demonstration of imatinib resistance caused by kinase mutations in patient samples.
31. Kreil S, Muller MC, Lahaye T, et al.: Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy [abstract]. Blood 2001, 98:435a. • Comprehensive analysis of mechanisms of resistance in large number of patients with CML at all stages of disease, demonstrating the pleiotropic nature of this problem.
32. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al.: Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002, 100:1014-1018.
33. Graham SM, Jorgensen HG, Allan E, et al.: Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99:319-325. • Raises the possibility that dormant stem cells could give rise to future relapse, even in patients with good initial responses.
34. Thiesing JT, Ohno-Jones S, Kolibaba KS, et al.: Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000, 96:3195-3199.
35. La Rosee P, O'Dwyer ME, Druker BJ: Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia 2002, 16:1213-1219.
36. Kano Y, Akutsu M, Tsunoda S, et al.: In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001, 97:1999-2007.
37. Topaly J, Zeller WJ, Fruehauf S: Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 2001, 15:342-347.
38. Hoover RR, Mahon FX, Melo JV, et al.: Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002, 100:1068-1071. • Shows that, at least in vitro, it is possible to overcome resistance using a combination of signal transduction inhibitors.
39. La Rosee P, Johnson K, O'Dwyer ME, et al.: In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 2002, 30:729-737.
40. O'Dwyer M: Multifaceted approach to the treatment of bcr-abl-positive leukemias. Oncologist 2002, 7(suppl 1):30-38.
41. Beelen DW, Graeven U, Elmaagacli AH, et al.: Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995, 85:2981-2990.
42. Hehlmann R, Hochhaus A, Kolb HJ, et al.: Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 1999, 94:3668-3677.
43. Pigneux A, Tanguy ML, Michallet M, et al.: Prior treatment with alpha interferon does not adversely affect the outcome of allogeneic transplantation for chronic myeloid leukaemia. Br J Haematol 2002, 116:193-201.
44. Lee SJ, Klein JP, Anasetti C, et al.: The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. Blood 2001, 98:3205-3211.
45. Hehlmann R: Trial of IFN or STI571 before proceeding to allografting for CML? Leukemia 2000, 14:1560-1562.
46. Hehlmann R, Berger U, Hochhaus A, et al.: Randomized comparison of early allogeneic related stem cell transplant vs. IFN-based therapy in newly diagnosed chronic myelogenous leukemia: first interim analysis of the German CML Study III. Blood 2001, 728a. • Randomized study showing early advantage for nontransplant therapy over SCT in low-risk and intermediate-risk patients.
47. Hasford J, Pfirrmann M, Hehlmann R, et al.: A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998, 90:850-858.
48. Gratwohl A, Hermans J, Goldman JM, et al.: Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998, 352:1087-1092.
49. Huntly BJ, Reid AG, Bench AJ, et al.: Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001, 98:1732-1738. • Identification of potentially important new prognostic factor in CML that is independent of stage.
50. Huntly BJ, Bench AJ, Delabesse E, et al.: Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. Blood 2002, 99:4547-4553.
51. Childs R, Epperson D, Bahceci E, et al.: Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a graft-versus-leukaemia effect. Br J Haematol 1999, 107:396-400.
52. Goldman JM, Druker BJ: Chronic myeloid leukemia: current treatment options. Blood 2001, 98:2039-2042. • Review article that provides a useful approach to decision making with respect to the difficult issue of SCT versus imatinib in newly diagnosed patients.
53. Olavarria E, Craddock C, Dazzi F, et al.: Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 2002, 99:3861-3862.
54. Kantarjian H, O'Brien S, Cortes J, et al.: Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002, 100:1590-1595.